LathMize® Green Platform Technology
A green chemistry and physical pharmacy platform that makes endogenous molecules shelf-stable, metabolically stable, and orally bioavailable.
Delivered where it is needed most
In a randomized, placebo-controlled trial, five days of oral dosing raised intracellular NAD by 53% versus placebo. Circulating plasma NAD did not change. These molecules are consumed inside cells, so where the increase happens matters as much as whether it happens.
What the platform does
Actively metabolized
Downstream metabolites rose sharply in the same trial: evidence the delivered molecule enters active metabolism rather than simply accumulating.
Stable without cold chain
Proprietary formulation preserves molecular integrity at ambient temperature, making practical distribution and long-term storage possible.
Built to scale
Waterless, low-energy processing without toxic solvents. One platform produces powder, lozenge, tablet and topical formats. Technology transfer to a cGMP, FDA-registered facility is complete.
Applied across multiple molecules
NAD+ is the first molecule to carry the platform into human data. BRY102, BRY103, and BRY104 follow on drug development paths.
Protected
pending patents covering composition, formulations and methods of use.
One platform, four programs
NAD+ carried the platform into human data. Three more programs follow on drug development paths.